Results 211 to 220 of about 407,207 (305)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Assessment of genetically modified soybean MON 87705 for renewal authorisation under Regulation (EC) No 1829/2003 (application GMFF-2023-21236). [PDF]

EFSA J
EFSA Panel on Genetically Modified Organisms (GMO), Casacuberta J, Barro F, Braeuning A, de Maagd R, Epstein MM, Frenzel T, Gallois JL, Koning F, Messéan A, Moreno FJ, Nogué F, Savoini G, Schulman AH, Tebbe C, Veromann E, Gómez JÁ, Goumperis T, Lenzi P, Lewandowska A, Camargo AM, Piffanelli P, Raffaello T, Gonzales ABG, Sánchez-Brunete E.   +24 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Safety and efficacy of a feed additive consisting of endo-1,4-beta-xylanase produced with <i>Bacillus subtilis</i>LMG S-15136 (Belfeed B MP/ML) (4a1606i) for all poultry species, suckling and weaned piglets, pigs for fattening, lactating sows and all minor porcine species other than reproductive animals for the renewal of its authorisation and the extension of its use to all <i>Suidae</i> (Puratos NV). [PDF]

EFSA J
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Villa RE, Azimonti G, Bonos E, Christensen H, Durjava M, Dusemund B, Gehring R, Glandorf B, Kouba M, López-Alonso M, Marcon F, Nebbia C, Pechová A, Prieto-Maradona M, Theodoridou K, Mayo B, Anguita M, Innocenti ML, Bozzi Cionci N, Brozzi R, Kolona M, Tarrés-Call J.   +22 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Applicant Demographics and Multiple Mini Interview Performance at a Medical School Over 5 Years.

JAMA Netw Open
Thompson TM, Park YS, Vela M, Tekian A.
europepmc   +1 more source

Safety assessment of the process Starlinger viscotec viscoZERO PET used to recycle post-consumer PET into food contact materials. [PDF]

EFSA J
EFSA Panel on Food Contact Materials (FCM), Lambré C, Crebelli R, da Silva M, Grob K, Milana MR, Pronk M, Rivière G, Ščetar M, Theodoridis G, Van Hoeck E, Waegeneers N, Dudler V, Papaspyrides C, Tavares Poças MF, Lioupis A, Lübke A, Tsochatzis E, Lampi E.   +18 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Safety of 3'-sialyllactose (3'-SL) sodium salt produced with a derivative strain (<i>Escherichia coli</i> K-12 MG1655 INB-3SL_01) of <i>E. coli</i> K-12 MG1655 (ATCC 700926) as a novel food pursuant to Regulation (EU) 2015/2283. [PDF]

EFSA J
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, Castenmiller J, De Henauw S, Jos Á, Maciuk A, Mangelsdorf I, McNulty B, Naska A, Pentieva K, Siani A, Thies F, Aguilera-Gómez M, Frenzel T, McArdle HJ, Moldeus P, Neuhäuser-Berthold M, Schlatter JR, van Loveren H, Fernández EN, Hirsch-Ernst KI.   +23 more
europepmc   +1 more source